Stockscreener 앱 받기
2.07
7.25%
0.14
시간 외 거래:
2.08
0.01
+0.48%
전일 마감가:
$1.93
열려 있는:
$1.95
하루 거래량:
6.45M
Relative Volume:
2.89
시가총액:
$451.64M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-7.3929
EPS:
-0.28
순현금흐름:
$-23.38M
1주 성능:
+18.29%
1개월 성능:
+10.70%
6개월 성능:
+46.81%
1년 성능:
+45.77%
1일 변동 폭
$1.92
$2.09
1주일 범위
$1.715
$2.09
52주 변동 폭
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.07 | 451.64M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Acquired by Barclays PLC - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
Equities Analysts Issue Forecasts for AKBA FY2024 Earnings - Defense World
What is HC Wainwright's Forecast for AKBA FY2024 Earnings? - MarketBeat
Brokers Set Expectations for AKBA FY2024 Earnings - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Increase in Short Interest - MarketBeat
Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat
Brokers Issue Forecasts for AKBA FY2029 Earnings - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from HC Wainwright - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at StockNews.com - MarketBeat
H.C. Wainwright optimistic on Akebia shares despite risks to commercial opportunity - Investing.com Nigeria
HC Wainwright Reiterates "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia announces ‘multiple positive business updates’ - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Jane Street Group LLC - Defense World
Akebia Therapeutics Announces Multiple Positive Business Updates - citybiz
Vafseo tablets start U.S. shipment, Akebia plans Phase 3 trial - Investing.com
Akebia's Vafseo Launch Secures Coverage for Nearly All U.S. Dialysis Patients, 99% of Doctors Show Interest - StockTitan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
Akebia Therapeutics (NASDAQ:AKBA) Upgraded at StockNews.com - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Holdings Lifted by Barclays PLC - Defense World
Geode Capital Management LLC Has $6.28 Million Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
New Strong Sell Stocks for January 3rd - Yahoo Finance
Akebia Therapeutics Awards Inducement Stock Options to New Employee at $1.90 Per Share - StockTitan
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Expands By 21.7% - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - MarketBeat
State Street Corp Purchases 683,287 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Purchased by State Street Corp - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Wellington Management Group LLP Takes $534,000 Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years - Yahoo Finance
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - The Eastern Progress Online
Akebia Therapeutics CEO to Present Vafseo Launch Updates at J.P. Morgan Healthcare Conference 2024 - StockTitan
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold Rating - MarketBeat
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - Kilgore News Herald
Akebia Therapeutics to Present at Upcoming Investor Conferences - The Eastern Progress Online
New Strong Sell Stocks for December 5th - Yahoo Finance
Akebia Therapeutics (FRA:AX9) EBITDA : €4.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Longview News-Journal
Akebia Begins Major Clinical Trial for FDA-Approved Anemia Drug Vafseo - StockTitan
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
0.08%
자본화:
|
볼륨(24시간):